Microport Scientific Corp. · HKEX:853
Microport Scientific — H1 2024 Earnings Presentation
22 slides from Microport Scientific's earnings presentation, Aug 30, 2024
Slide 1: MicroPort Scientific Corporation 2024 Interim Results
MicroPort Scientific Corporation 2024 Interim Results 30 August 2024
Slide 2: Disclaimer
Disclaimer This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of,
Slide 3: Contents
Contents Company Highlights Business Review Financial Review Appendix – Financial Statements
Slide 4: Strong Results Underpinned by Strategic Focus and Transformation Efforts
Strong Results Underpinned by Strategic Focus and Transformation Efforts Company Highlights Transformation Underway Reshaping our business with full P&L responsibility and to create shareholder value Strategic Priorities 1H2024 Progress Revenue$558.7 mn 17.0%YOY Category Leadership Leading mark
Slide 5: Positive Momentum Across Business Segments
Positive Momentum Across Business Segments Company Highlights Rapid Revenue Growth Diversified Business YoY China Revenue Revenue Segment Revenue Changes YoY Changes by Segment 19.8% ▲9.0% ▲32.5% 5.6% Orthopedics $126.3mn Cardiovascular 10.2% CRM CRM $113.4mn ▲5.6% ▲61.5% 20.3% Multi Structural He
Slide 6: Substantially Expense Reduced & Cost Effectiveness Increased
Substantially Expense Reduced & Cost Effectiveness Increased Company Highlights Operating expense Operating expense ratio USD: million -22% -30ppts Improved Operating Efficiency 453 94% 355 64% 23H1 24H1 23H1 24H1 2024 Interim Results R&D Expenses Admin expenses S&M expenses USD: million USD: millio
Slide 7: Expanding Our International Presence With Broad-based Capabilities
Expanding Our International Presence With Broad-based Capabilities Company Highlights Overseas Registration/Approval Global Footprint Global Patents Layout 100+ YTD Covered 100+ Incl. 300+ YTD 4 FDA and 11 CE Countries& Region (incl. applications) in total 2024 Interim Results 1300+ in total I
Slide 8: Contents
Contents Company Highlights Business Review Financial Review Appendix – Financial Statements
Slide 9: Cardiovascular Business: Net Profit Substantially Increased by 279.4% YOY
Cardiovascular Business: Net Profit Substantially Increased by 279.4%YOY Business Review Most Complete Product Pipeline In Coronary Field Key Financials Complete & Diversified Product Pipeline Argusclarity® Argusclarity® Diagnostic Device Revenue Net Profit Insight-100 Insight-100h USD: million USD:
Slide 10: Orthopedics Business: Positive EBITDA Achieved
Orthopedics Business：Positive EBITDA Achieved Business Review Revenue Increased By 9.0% YoY Non-China Business China Business Revenue Breakdown by region Revenue Joint products USD: million USD: million +6.4% USD: million EMEA +32.5% +55.5% 38% 104.2 111.2 15.1 +22.5% 11.1 2024 Interim Results 1H 24
Slide 11: CRM Business: EBITDA significantly improved
CRM Business: EBITDA significantly improved Business Review Revenue Increased By 5.6%YoY Non-China Business China Business Revenue Revenue Key products USD: million USD: million USD: million 10.2 101.4 +61.5% +50.8% 11.9 +1.3% 7.8 1H23 +64.6% 6.7 1H24 100.5 2024 Interim Results 1.2 1.9 1H23 1H24 1H2
Slide 12: Endovascular Business
Endovascular Business Business Review Product Pre-clinical Clinical Registration Key Financials L-REBOA® Aortic Occlusion Balloon Obtained NMPA approval Operating Profit Net Profit Catheter Revenue • Submitted for NMPA review USD: million USD: million USD: million +26.3% +44.5% Aortic Intervention
Slide 13: Neurovascular Business
Neurovascular Business Business Review Product Pre-clinical Clinical Registration Key Financials Tubridge Plus® Revenue Net Profit Operating Profit NMPA approved in Aug 2024 HS Flow-diverting Stent USD: million USD: million USD: million 62% Hemorrhagic Stroke 1H 2024 Numen Silk® 3D Electroically
Slide 14: Structural Heart Business
Structural Heart Business Business Review Product Pre-clinical Clinical Registration Key Financials Revenue Gross Profit Margin Total Net Loss Obtained NMPA approval VitaFlow Liberty® USD: million USD: million 1H23 1H24 USD: million Obtained CE approval +26.7% +4.8% 25.0 31.1 66.1 70.9 (7.7) Vit
Slide 15: Surgical Robot Business
Surgical Robot Business Business Review Product Pre-clinical Clinical Registration Key Financials Revenue Total Net Loss Toumai® Laparoscopic Obtained NMPA approval USD: million USD: million 1H23 1H24 Surgical Robot Obtained CE marking Laparoscopic +117.0% 10.0 Toumai® Remote Laparoscopic 4.9 (3
Slide 16: Contents
Contents Company Highlights Business Review Financial Review Appendix – Financial Statements
Slide 17: Consolidated Financial Performance
Consolidated Financial Performance Financial Review Revenue Gross Profit Margin USD: million +17.0% 558.7 2024 Interim Results 59.8% 59.2% 482.6 1H23 1H24 1H23 1H24 Operating Expenses Non-HKFRS Adjusted Net Loss& Total Net Loss USD: million USD: million 500.0 94% 100.0% Non-HKFRS adjusted net loss T
Slide 18: Operating Expenses
Operating Expenses Financial Review R&D Expenses Administrative Expenses Sales & Marketing Expenses 300.0 60.0% 300.0 40.0% USD: million USD: million USD: million 300.0 50.0% 250.0 50.0% 35.0% 45.0% 250.0 250.0 38.8% 30.0% 35.2% 40.0% 200.0 40.0% 200.0 35.0% 25.0% 200.0 19.9% 27.9% 30.0% 2024 Interi
Slide 19: MicroPort
MicroPort 00:00:05 115 30 . + +++ 4 ++ ooeose Eyes for greatness Hands on details ++ ooo +e oee
Slide 20: Appendix – Consolidated Income Statement
Appendix – Financial Statement Consolidated Income Statement USD'000 2024 1H 2023 1H Var. Revenue 558,702 482,605 15.8% Cost of sales (228,122) (194,189) 17.5% Gross profit 330,580 288,416 14.6% Other net income (68) 17,039 -100.4% Research and development costs (115,033) (187,334) -38.6% Distributi
Slide 21: Appendix – Consolidated Balance Sheet
Appendix – Financial Statement Consolidated Balance Sheet USD'000 30 June 2024 31 Dec 2023 Var. Non-current assets Investment properties 6,087 6,256 -3% Property, plant and equipment 978,657 1,004,573 -3% Intangible assets 236,699 234,435 1% Goodwill 147,271 149,393 -1% Equity-accounted investees 37
Slide 22: Consolidated Balance Sheet (cont'd)
Consolidated Balance Sheet (cont’d) Appendix – Financial Statement USD'000 30 June 2024 31 Dec 2023 Var. Non-current liablities Interest-bearing borrowings 801,523 508,330 58% Lease liabilities 74,107 85,327 -13% Deferred income 50,110 42,344 18% Convertible bonds 341,841 213,267 60% Contract liabil